[Peritoneal dissemination of ovarian cancer and tumor angiogenesis].
Baba
Tsukasa
T
Department of Gynecology and Obstetrics, Faculty of Medicine, Kyoto University.
Mandai
Masaki
M
Fujii
Shingo
S
D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000964:Antimetabolites, Antineoplastic / Q000627:therapeutic use; D000068258:Bevacizumab; D000069287:Capecitabine; D003841:Deoxycytidine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D005260:Female; D005472:Fluorouracil / Q000031:analogs & derivatives; D006801:Humans; D009389:Neovascularization, Pathologic / Q000235:genetics*; D010051:Ovarian Neoplasms / Q000098:blood supply* / Q000188:drug therapy / Q000473:pathology*; D010534:Peritoneal Neoplasms / Q000098:blood supply* / Q000188:drug therapy / Q000473:pathology / Q000556:secondary*; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors / Q000502:physiology
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000964:Antimetabolites, Antineoplastic; D042461:Vascular Endothelial Growth Factor A; D003841:Deoxycytidine; D000068258:Bevacizumab; D000069287:Capecitabine; D005472:Fluorouracil